Marvel Biosciences Announces Grant of Deferred Share Units

Sep 1, 2026 | News

Calgary, Alberta, Canada, September 1, 2026 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units (“DSUs”) to Marvel’s...

Marvel Biosciences Expands Private Placement to Quebec

Aug 19, 2026 | News

Calgary, Alberta ‐ August 19, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors...

Marvel Biosciences Announces Private Placement Up to $3 Million

Jul 16, 2026 | News

Calgary, Alberta ‐ July 16, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) is pleased to announce that it intends to complete a non‐brokered private placement offering (the “Offering”) of units of the...